Search PubMed⌕ Search

Biomedical subjects

G Read

Publications and source records attributed to G Read.

At least 19 recordsLinked to original sources
PubMed2001

The assessment of irradiated bladder carcinoma using dynamic contrast-enhanced MR imaging.

AIM: To evaluate the role of dynamic contrast-enhanced magnetic resonance imaging (DCEMRI) in distinguishing residual or recurrent tumour from radiation change in patients with bladder carcinoma. MATERIALS AND METHODS: Forty patients with biopsy proven bladder carcinoma were imaged before and at 4 and 12 months after radiotherapy (XRT) using conventional and dynamic contrast-enhanced magnetic resonance imaging at 0.5 Tesla. An enhancement of >1.54 times above baseline at 80 s post-contrast injection proved a reliable indicator of tumour before radiotherapy and was therefore applied to the assessment of patients after XRT. Conventional MR images and dynamic enhancement profiles (DEPs) from the site of previous tumour were scored by three radiologists for the presence of tumour at 4 and 12 months after XRT. Findings were compared with cystoscopic biopsy. RESULTS: Dynamic contrast-enhanced magnetic resonance imaging had negative predictive values of 100% and 93% for tumour recurrence at 4 and 12 months, respectively. The positive predictive values, sensitivity and specificity were 48, 100 and 48% at 4 months and 50, 80 and +76% at 12 months post XRT, respectively. CONCLUSION: Dynamic contrast-enhanced magnetic resonance imaging may prove reliable in excluding the presence of persistent or recurrent tumour up to 12 months after XRT.

Contrast Media↗
PubMed2000

Relationship of MRI and clinical staging to outcome in invasive bladder cancer treated by radiotherapy.

AIM: To compare MRI and clinical staging of invasive bladder cancer prospectively and identify additional prognostic features on MRI before radiotherapy. METHODS AND MATERIALS: 143 patients with a pathological diagnosis of transitional cell carcinoma underwent MRI (1.0 T) of the abdomen and pelvis before radical radiotherapy. Tumour size, site, degree of infiltration, presence of adenopathy and hydronephrosis were assessed and an appropriate radiological stage assigned. Following radiotherapy all patients received regular cystoscopic follow-up. Date of first relapse and date of death were recorded. RESULTS: The median follow-up was 2.8 years for survivors. Those patients upstaged from T2a clinically to T3b on MRI had a significantly worse outcome (P = 0.0078). In univariate analysis a number of MRI features were significantly associated with adverse outcome: tumour size, circumferential tumour extent, and presence of hydronephrosis (all P < 0.05). After adjustment for clinical T stage and histological grade, all these MRI features and the MRI T stage were found to confer additional prognostic information in predicting early disease relapse and death (P < 0.05). CONCLUSION: This study demonstrates that MRI before radiotherapy provides valuable additional prognostic information compared to clinical staging.

Aged↗
PubMed1999

Undetectable urinary free cortisol concentrations in a case of Cushing's disease.

Measurement of the 24-h urinary free cortisol is a valuable screening test of endogenous hypercortisolism and, although false positive results may occur in a few situations, for example endogenous depression, false negative results are unusual. We report a case of a 48-year-old lady with pituitary-dependent Cushing's disease, whose 24-h urinary free cortisol excretion was consistently undetectable in association with increased plasma and salivary cortisol concentrations and reduced dexamethasone suppressibility. The patient had chronic renal impairment (creatinine clearance 21 ml/min) as a consequence of hypertension, despite only modestly increased urea and creatinine concentrations. Urinary free cortisol measurements must be interpreted with caution in patients with renal impairment.

Creatinine↗
PubMed1998

Clinical variability of target volume description in conformal radiotherapy planning.

PURPOSE: The pivotal step in radiation planning is delineation of the target volume and production of a treatment plan to encompass this. This study assesses the variation of physicians in creation of these volumes. METHODS AND MATERIALS: Three radiologists and eight radiation oncologists outlined the gross tumour volume (GTV) on the planning CT scans of four cases with T3 bladder cancer. In addition, the radiation oncologists (RO) created a planning target volume according to a set protocol for all cases. Volumes were produced and comparison of these volumes and the position of the isocenters were analysed. In addition, the margins allowed were measured and compared. RESULTS: There was a maximum variation ratio (largest to smallest volume outlined) of the GTV in the four cases of 1.74 among radiologists and 3.74 among oncologists. There was a significant difference (p = 0.01) in mean GTV between RO and the radiologists. The mean GTV of the RO exceeded the radiologists by a factor of 1.29 with a mean difference of 13.4 cm3. The variation ratio in PTV among oncologists ranged from 1.25 to 3.33. There was no significant difference in mean PTV values between the two groups of ROs divided by specialization in uro-oncology. The mean variation in location of the isocenter from the centroid of the radiologists' volume in the four cases was from 2.6 to 5.7 mm. There was, however, a wide range of values from 1.4 mm to 24.1 mm. Median margin per case ranged from 14.7 to 18.7 mm. Minimum margins allowed in each case varied from minus 7 mm to 9 mm. CONCLUSION: This study demonstrates significant interphysician variability in producing target volumes and radiation plans for conformal radiotherapy. The scale of this difference is clearly of significance, with up to 3-fold variation in volumes delineated by clinicians. The factors leading to these differences will be further addressed. The existence of such variability, however, clearly needs to be accepted as a factor in the overall uncertainty analysis in conformal radiotherapy planning.

Humans↗
PubMed1997

Bladder movement during radiation therapy for bladder cancer: implications for treatment planning.

PURPOSE: To describe and quantify bladder movement during radical radiation therapy (RT). To attempt to identify factors that predict for excessive alterations in bladder position. To use the above information to assist in defining the "adequate" planning target volume margin. METHODS AND MATERIALS: Thirty patients with bladder cancer suitable for radical courses of RT were followed prospectively. Patients had an initial planning computerized tomography (CT) scan of the pelvis and three subsequent scans performed weekly during the treatment period. The following measurements were made on each scan in the midbladder slice: maximum anteroposterior (AP) and lateral bladder dimensions, AP rectal diameter, and the distance (margin) between the bladder walls (anterior, posterior, right, and left lateral) and the 95% isodose line. Various patient and tumor data, including bladder and bowel symptoms, were recorded to attempt correlation with bladder movement. RESULTS: Bladder size: the median bladder size (area) over all scans in all patients was 36.9 cm2 (range: 16.2 to 80.9 cm2). The change in bladder area across each sequence varied from 3.3 to 29.1 cm2 (7-55% change in area between scans). Patients with bladders of larger than the median size on the planning scan (despite emptying) were more likely to have alteration in size than those with small bladders, and this change was in the direction of contraction (p = 0.01). Bladder displacement: bladder wall movement of > 1.5 cm was defined as "significant." Eighteen of 30 patients (60%) demonstrated "significant" movement of at least one bladder wall relative to the original isodose plot. Movement resulting in margin reduction occurred in 10 patients (33%). Two patients required treatment replanning due to consistently altered bladder position. There was no pattern to displacement through RT, and all walls were at approximately equal risk of movement. Factors influencing bladder movement: posterior bladder wall movement appeared to relate to "marked" (>2 cm) rectal diameter change. There was a trend for patients with larger amounts of residual bladder tumor (greater than the median) to exhibit more bladder movement; 11 of 14 "moved" compared with 7 of 16 patients with less residual tumor. Other clinical factors including age, sex, body size, acute RT reaction, and tumor stage did not appear to relate to bladder movement. CONCLUSION: Bladder movement during RT is clinically relevant and is random with respect to both time and direction. We recommend, at least with respect to tumor-bearing regions of the bladder, that no less than a 2.0 cm margin should be allowed.

Aged↗
PubMed1997

Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy.

Prognostic factors for 3-year progression-free survival (PFS) were defined in 286 patients with advanced seminoma treated with cisplatin-based chemotherapy at 10 European oncology units (no prior treatment: 236; prior radiotherapy: 50). Previously irradiated patients displayed a 69% PFS as compared to 87% in those presenting with advanced seminoma at the time of diagnosis (P = 0.009). In the univariate analysis, the extent and site of disease before chemotherapy and the level of serum LDH (< 2.0 versus > or = 2.0 x upper limit of normal) correlated with PFS in previously non-irradiated patients, but not in patients with prior radiotherapy. The multivariate analysis was, therefore, restricted to previously non-irradiated patients. The presence of non-pulmonary visceral metastases and a serum LDH level of > or = 2 x normal (N) proved to be independent prognostic factors. Based on these variables, two prognostic models were constructed and validated in an external data set of 166 comparable patients. For clinical use, Model 2 is recommended. The good-prognosis group comprises non-irradiated patients with stage II seminoma and any LDH level at presentation, or stage III and IV patients (with lung metastases only) whose serum LDH level is < 2 x N. These patients display a 94% 3-year PFS. The poor prognosis group includes all other patients with a 56% PFS. With this prognostic model, individualisation of the therapeutic approach may be considered in patients with advanced seminoma and a high risk of chemotherapy-related toxicity.

Adult↗
PubMed1997

Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party.

In a retrospective study, data from 302 patients with metastatic testicular seminoma treated with chemotherapy between 1978 and 1990 in 10 European centres were analysed to evaluate the role, if any, of postchemotherapy treatment with irradiation. The primary endpoint of this study was the progression-free survival rate after chemotherapy with or without additional radiotherapy. This was related to the type of primary chemotherapy, sites and sizes of pre- and postchemotherapy masses, the extent of surgical resection after chemotherapy and the use of radiotherapy. 174 patients had residual disease at the end of chemotherapy. The most important prognostic factors for progression were the presence of any visceral metastases or raised LDH prechemotherapy, and the presence of residual disease at visceral sites after chemotherapy. Approximately half the patients with residual masses underwent postchemotherapy radiotherapy, with selection based predominantly on institutional practice. In patients receiving platinum-based chemotherapy, no significant difference was detected in progression-free survival whether or not radiotherapy was employed. Patients receiving BEP (bleomycin, etoposide and cisplatin) had a progression-free survival rate of 88% (95% CI, 80-96%) uninfluenced by postchemotherapy radiotherapy. In patients with residual masses confined to the abdomen after platinum-based chemotherapy, the absolute benefit to radiotherapy was estimated to be 2.3%. The potential benefit of postchemotherapy radiotherapy is minimal, and so it is concluded that the use of adjuvant radiotherapy to residual masses after platinum-based chemotherapy for metastatic seminoma is unnecessary.

Abdominal Neoplasms↗
PubMed1997

Predicting late rectal complications following prostate conformal radiotherapy using biologically effective doses and normalized dose-surface histograms.

A model to predict the late normal tissue complication probability (NTCP) of the rectum following conformal therapy is described. The model evaluates the biological consequence of inhomogeneities in the physical dose by computing dose histograms of the biologically effective dose to the surface of the rectum for a given fractionation scheme. A method of normalizing the surface area of the rectum is employed so that the predicted NTCP is independent of the differing cross-sectional size of sections of the rectum, ensuring the NTCP is dependent only on the dose delivered to sensitive rectal tissues. The model has been used to assess severe late rectal complications and the milder RTOG grades 2 and 3 reactions. This model was found to predict severe toxicity levels of 1.7 +/- 0.6% for an accelerated treatment of 50 Gy in 16 fractions commonly employed at this centre. This result lies between the severe toxicities predicted for 60 and 62 Gy delivered in 2 Gy fractions. The model predicts that the average NTCP for severe late effects for nine prostate patients becomes greater than 5% with a fractionation scheme of 70 Gy in 35 fractions, for the four fields treatment. The effects of not treating all fields at each therapy session on rectal toxicity were also investigated. Biologically effective dose-surface histograms show that the dose to the lower surface of the rectum is increased by not treating all fields at each therapy session, but the predicted differences in rectal NTCP are negligible.

Dose-Response Relationship, Radiation↗
PubMed1996

Cardiff puerperal mood and hormone study. III. Postnatal depression at 5 to 6 weeks postpartum, and its hormonal correlates across the peripartum period.

BACKGROUND: We assessed associations of mood at 5-6 weeks postpartum with peripartum saliva cortisol and progesterone profiles. METHOD: A prospective study involved 120 primiparous women free of major marital, socioeconomic and health problems, who collected saliva twice daily from 2 weeks before delivery to day 35 postpartum. This allowed intensive characterisation of cortisol and progesterone profiles. At the conclusion of the study, mood was assessed according to standard criteria. RESULTS: Seven women developed major depression according to DSM-III-R criteria. No associations emerged between progesterone and mood at 5 to 6 weeks. Lower levels of evening cortisol in the immediate peripartum period, were associated with postnatal depression. CONCLUSION: The study provides no support for the treatment strategy of progesterone augmentation following delivery, as a prophylactic against postnatal depression. The HPA axis and its associations with postnatal mood warrants further investigation.

Adolescent↗
PubMed1994

Estimating the cost of radiotherapy.

Estimates of the cost of radiotherapy vary and depend upon the purpose for which the calculation is made and the detail of the component items taken into consideration. Capital costs and their revenue consequences are more significant in radiotherapy than in many other clinical specialties but other factors such as staff costs and maintenance must be taken into consideration. Three published UK studies have been reviewed in which the cost per fraction of radiotherapy was estimated to lie between 22 pounds and 38 pounds in 1989. These values have been used to calculate the possible costs for courses of radiotherapy of differing durations. However, these simple estimates may be misleading and the use of Healthcare Resource Groups, based upon the complexity of radiotherapy planning and the number of fractions, is suggested. Two UK studies estimating the costs of providing a radiotherapy service to a peripheral hospital were also reviewed. The approximate cost of a new referral to a peripheral clinic was estimated to lie between 880 pounds and 1260 pounds in 1989.

Ambulatory Care Facilities↗
PubMed1994

Determination of octadecadienoic acids in human serum: a critical appraisal.

The method based on high-performance liquid chromatography currently used to determine the lipid levels of octadeca-9(Z),11(E)-dienoic acid in human serum fails to distinguish between this acid and octadeca-10(E),12(Z)-dienoic acid. Adducts with the fluorescent dienophile 4-[3-(1-propenyl)propyl]-1,2,4-triazoline-3,5-dione permit the separation of these two isomeric acids as does gas-liquid chromatography of their methyl esters, but these alternatives produce equivocal results when applied to biological samples.

Chromatography, Gas↗
PubMed1994

Prenatal testosterone levels in XXY and XYY males.

It has been postulated that behavioural differences between normal males and those with an additional X or Y chromosome may be related to pre- or postnatal hormonal variations. The prenatal hormone status was investigated using amniotic fluid obtained at antenatal diagnosis between 16 and 20 weeks gestation from fetuses with sex chromosome abnormalities and from controls of the same gestational age. After log transformation, the (geometric) mean testosterone levels were XY 439.4 pmol/l, range 165-1,027 (n = 29), XYY 490.7 pmol/l, range 224-1,092 (n = 20); and XXY 419 pmol/l, range 87-1,021 (n = 20). There were no significant differences between the three male groups and all three were significantly higher than the XX fetuses at 147.0 pmol/l, range 41-474 (p < 0.001). These findings give no support to the hypothesis that prenatal testosterone levels contribute to later behavioural characteristics.

Amniotic Fluid↗
PubMed1993

Magnetic resonance imaging with Gadolinium-DTPA for assessment of bladder carcinoma and its response to treatment.

Magnetic Resonance Imaging (MRI) with intravenous Gadolinium-DTPA (Gd-DTPA, Magnevist, Schering-AG) was performed in 44 patients, 32 with primary bladder carcinoma and 12 with suspected recurrence after treatment. Gd-DTPA often increased diagnostic confidence in the identification and staging of tumours confined to the bladder wall and was necessary to assess depth of bladder wall invasion when T2-weighted images were suboptimal. Enhancement after Gd-DTPA enabled distinction between necrotic and viable tumour and blood clot. There was little advantage in its use for tumours infiltrating perivesical fat or with metastases to lymph nodes or bone, in the absence of a fat suppression sequence. Gd-DTPA may therefore be useful in selected patients with tumours of Stage T3a or less in whom information about depth of bladder wall invasion is inadequately shown on pre-contrast sequences. Artefacts due to variable and inhomogeneous urine signal intensity, however, often degraded post-Gd-DTPA images of the bladder. Changes in the bladder due to radiotherapy were observed on MRI 3-4 months after treatment in patients referred for routine follow-up and in some patients with suspected recurrence. Mucosal hyperintensity, thickening and abnormal signal intensity of the muscular layers of the bladder wall, with enhancement after Gd-DTPA were demonstrated. Such changes obscured small volume or superficial recurrence of tumour after radiotherapy. Abnormal enhancement was also observed in pelvic organs and soft tissues irradiated several years earlier. Enhancement after Gd-DTPA does not therefore reliably distinguish between recurrent tumour and radiotherapy change.

Aged↗
PubMed1993

Short duration radiotherapy in stage I seminoma of the testis: preliminary results of a prospective study.

Ninety-four patients with Stage I seminoma of the testis, treated between November 1989 and December 1991, received short duration radiotherapy (2000 cGy in 8 fractions) to the para-aortic area only. The treatment was well tolerated and, after a median follow-up time of 34 months (minimum 15 months), no patient has relapsed in the abdomen. One patient developed an apparently solitary distant metastasis from a latent teratoma and is disease free after chemotherapy. This form of radiotherapy would appear to be well-tolerated with a low relapse rate. It offers the advantage of a simpler and shorter technique compared with conventional therapy and avoids the necessity of intensive surveillance to detect relapse.

Adult↗